<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugFinancialsOutput id="42147" name="fidaxomicin"><DrugSalesAndForecastCommentary>&lt;para&gt;&lt;subtitle&gt;Consensus Sales Information&lt;/subtitle&gt;Consensus forecast data, where available, are presented for &lt;ulink linkType="Company" linkID="18077"&gt;Merck &amp;amp; Co&lt;/ulink&gt; (the parent company of &lt;ulink linkType="Company" linkID="21697"&gt;Cubist Pharmaceuticals&lt;/ulink&gt; which acquired originator Optimer), &lt;ulink linkType="Company" linkID="1044298"&gt;Specialised Therapeutics Australia&lt;/ulink&gt;, &lt;ulink linkType="Company" linkID="1013295"&gt;Astellas&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Reported Annual Sales&lt;/subtitle&gt;Sales of fidaxomicin (Dificlir) reported by Astellas for FY  ended March 31, 2016 were JPY 2.6 billion ($24.188 million), representing  a year-on-year  increase of 29.0% on FY ended March 31, 2015 [&lt;ulink linkType="Reference" linkID="1766222"&gt;1766222&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Regional Development and Marketing Rights&lt;/subtitle&gt;In May 2005, originator Optimer and &lt;ulink linkType="Company" linkID="28968"&gt;Par Pharmaceutical&lt;/ulink&gt; signed an agreement for the development and commercialization of fidaxomicin. Optimer  was to fund the clinical trials conducted by Par, which  would be responsible for filing the NDA and commercialization of the product in the US and Canada [&lt;ulink linkType="Reference" linkID="598998"&gt;598998&lt;/ulink&gt;]. However, in February 2007, Optimer reacquired rights [&lt;ulink linkType="Reference" linkID="765065"&gt;765065&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="768860"&gt;768860&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="768895"&gt;768895&lt;/ulink&gt;], although would continue to pay Par royalties  [&lt;ulink linkType="Reference" linkID="1529582"&gt;1529582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2010, &lt;ulink linkType="Company" linkID="1089119"&gt;OBI Pharma&lt;/ulink&gt; acquired exclusive commercial rights to fidaxomicin in Taiwan [&lt;ulink linkType="Reference" linkID="1490734"&gt;1490734&lt;/ulink&gt;].  In October 2015, Merck entered into an exclusive agreement with OBI to develop and commercialize fidaxomicin for treatment of  CDAD in Taiwan [&lt;ulink linkType="Reference" linkID="1699989"&gt;1699989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, Astellas signed an exclusive licensing agreement with Optimer to develop and commercialize fidaxomicin in Europe and certain other countries in the Middle East, Africa and the Commonwealth of Independent States [&lt;ulink linkType="Reference" linkID="1166261"&gt;1166261&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1167015"&gt;1167015&lt;/ulink&gt;]. In March 2012, Astellas also acquired exclusive Japanese development and commercialization rights from Optimer  [&lt;ulink linkType="Reference" linkID="1275897"&gt;1275897&lt;/ulink&gt;]. In February 2014, Cubist stated that with the acquisition of Optimer it had acquired the collaboration and license agreement and a supply agreement with Astellas; Cubist would be the exclusive supplier of fidaxomicin for Astellas in the Astellas territories. The agreements would expire on a product-by-product and country-by-country basis when a generic product takes a specified market share of the applicable fidaxomicin product in the applicable country [&lt;ulink linkType="Reference" linkID="1529582"&gt;1529582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, Optimer  and Cubist  agreed an exclusive deal to copromote fidaxomicin in the US for 2 years from the first commercial sale [&lt;ulink linkType="Reference" linkID="1181978"&gt;1181978&lt;/ulink&gt;]. In October 2013, Cubist   acquired  Optimer  [&lt;ulink linkType="Reference" linkID="1491823"&gt;1491823&lt;/ulink&gt;]. In January 2015, Merck &amp;amp; Co acquired Cubist  [&lt;ulink linkType="Reference" linkID="1627968"&gt;1627968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, Optimer granted Specialised Therapeutics Australia exclusive marketing rights in Australia and New Zealand [&lt;ulink linkType="Reference" linkID="1302254"&gt;1302254&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1527340"&gt;1527340&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, Optimer entered into an exclusive agreement with AstraZeneca for the commercialization of fidaxomicin in South America, including Brazil, Central America, Mexico and the Caribbean, for the treatment of Clostridium difficile infection. AstraZeneca acquired the commercialization rights in these regions [&lt;ulink linkType="Reference" linkID="1346318"&gt;1346318&lt;/ulink&gt;].&lt;/para&gt;</DrugSalesAndForecastCommentary><Financials><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2002</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2003</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2004</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2005</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2006</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2007</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2008</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2009</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2010</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2011</Year><Region>US</Region><Sales>21.5</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2011</Year><Region>WW</Region><Sales>21.5</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2012</Year><Region>US</Region><Sales>62.4</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2012</Year><Region>WW</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2012</Year><Region>WW</Region><Sales>62.4</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2012</Year><Region>WW - US</Region><Sales>0</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="21697">Cubist Pharmaceuticals Inc</Company><Year>2013</Year><Region>US</Region><Sales>12.2</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2013</Year><Region>US</Region><Sales>56</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2013</Year><Region>WW</Region><Sales>6.64</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="21697">Cubist Pharmaceuticals Inc</Company><Year>2013</Year><Region>WW</Region><Sales>12.2</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>50</PublicationAnnualPriority></Financial><Financial><Company id="29549">Optimer Pharmaceuticals Inc</Company><Year>2013</Year><Region>WW</Region><Sales>56</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2013</Year><Region>WW - US</Region><Sales>6.64</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="21697">Cubist Pharmaceuticals Inc</Company><Year>2014</Year><Region>US</Region><Sales>47.7</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2014</Year><Region>WW</Region><Sales>12.35</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="21697">Cubist Pharmaceuticals Inc</Company><Year>2014</Year><Region>WW</Region><Sales>47.7</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2014</Year><Region>WW - US</Region><Sales>12.35</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2015</Year><Region>US</Region><Sales>93</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2015</Year><Region>WW</Region><Sales>16.6</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2015</Year><Region>WW</Region><Sales>93</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2015</Year><Region>WW - US</Region><Sales>16.6</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast><PublicationAnnualPriority>20</PublicationAnnualPriority></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2016</Year><Region>US</Region><Sales>115</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2016</Year><Region>WW</Region><Sales>24.188</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2016</Year><Region>WW</Region><Sales>115</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2016</Year><Region>WW - US</Region><Sales>24.188</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2017</Year><Region>US</Region><Sales>160</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2017</Year><Region>WW</Region><Sales>160</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2018</Year><Region>US</Region><Sales>190</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2018</Year><Region>WW</Region><Sales>190</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>N</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2019</Year><Region>WW</Region><Sales>220</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2020</Year><Region>WW</Region><Sales>22.675</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2020</Year><Region>WW</Region><Sales>250</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="1013295">Astellas Pharma Inc</Company><Year>2021</Year><Region>WW</Region><Sales>29.024</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2021</Year><Region>WW</Region><Sales>280</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2022</Year><Region>WW</Region><Sales>310</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2023</Year><Region>WW</Region><Sales>340</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial><Financial><Company id="18077">Merck &amp; Co Inc</Company><Year>2024</Year><Region>WW</Region><Sales>370</Sales><NumberOfPublications>1</NumberOfPublications><Forecast>Y</Forecast></Financial></Financials></drugFinancialsOutput>